Page 6 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Basilea Pharmaceutica AG: Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45 75 million

Basilea Pharmaceutica AG: Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45 75 million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Basel stadtUnited statesUnited kingdomNils schrBryan garnierDavid veitchHead of corporate communications investor relationsCredit suisseFinancial servicesSwiss exchangeBasilea pharmaceutica ltdUnited kingdom european union withdrawalSwiss financial servicesCantor fitzgeraldEuropean unionSwiss exchange on

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Basel stadtUnited statesUnited kingdomNils schrBryan garnierHead of corporate communications investor relationsCredit suisseFinancial servicesBasilea pharmaceutica ltdUnited kingdom european union withdrawalSwiss exchangeSwiss financial servicesCantor fitzgeraldEuropean unionSwiss exchange onPharmaceutica ltd

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding Basel, Switzerland, February 23, 2021 Basilea Pharmaceutica Ltd ( Basilea or the Company ) announced today the launch of an offering of up to 1 million new registered shares with a par value of CHF 1.00 per share. The net proceeds from this private placement will be used for i) the clinical development of Basilea s clinical oncology drug candidates derazantinib and lisavanbulin, ii) pre-clinical research and development activities, and iii) working capital and other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets. The new shares correspond to approximately 8% of Basilea s currently issued share capital and will be issued from the Company s authorized share capital, excluding subscription rights of existing shareholders. The offer price of the new shares will be determined in an accelerated bookbuil

Basel stadtUnited statesUnited kingdomNils schrBryan garnierHead of corporate communications investor relationsCredit suisseFinancial servicesSwiss exchangeBasilea pharmaceutica ltdUnited kingdom european union withdrawalSwiss financial servicesCantor fitzgeraldEuropean unionBasilea pressSwiss exchange on

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets Operating loss reduced by over 50% to CHF 8.2 million Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments Established clinical proof of concept for derazantinib as monotherapy in first cancer indication 2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 - 120 million Basel, Switzerland, February 16, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020. David Veitch, Chief Executive Officer, said: Despite the coronavirus pandemic, we have remained fully operational and have achieved significant milestones throughout 2020, both in the commercialization of our two marketed brands, Cresemba and Zevtera, as well

United statesBasel stadtNils schrAsahi kaseiMarc engelhardtEli lillyDavid veitchAsia pacificCresemba zevteraAdesh kaulHead of corporate communications investor relationsArqule incMerck co incAdult brain tumor consortiumVirtual congressBiomedical advanced research

Basilea reports strong 2020 financial results and significant progress in the clinical pipeline

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Basilea reports strong 2020 financial results and significant progress in the clinical pipeline . Basilea Pharmaceutica AGFebruary 16, 2021 GMT Double-digit growth in Cresemba and Zevtera non-deferred revenue contributions Operating loss reduced by over 50% to CHF 8.2 million Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments Established clinical proof of concept for derazantinib as monotherapy in first cancer indication 2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 - 120 million Basel, Switzerland, February 16, 2021 ADVERTISEMENT Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020.

Basel stadtNils schrAsahi kaseiMarc engelhardtEli lillyDavid veitchAsia pacificCresemba zevteraAdesh kaulHead of corporate communications investor relationsDrug administrationBasilea pharmaceutica ltdSwiss exchangeAdult brain tumor consortiumVirtual congressChief executive officer